Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Renal Cell 6Melanoma 5Clear-cell metastatic renal cell carcinoma 4Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sjogren's Syndrome 1Scleroderma, Systemic 1Psoriasis 1Prostatic Neoplasms 1Penile Neoplasms 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Sclerosis 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lupus Erythematosus, Systemic 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Inflammatory Bowel Diseases 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 25Paclitaxel 20Carboplatin 17Bevacizumab 12Specimen Handling 10Letrozole 10abemaciclib 7dostarlimab 6Taxes 6Blood Specimen Collection 6Medroxyprogesterone Acetate 5Magnetic Resonance Spectroscopy 5Fulvestrant 5Drug Therapy 5Doxorubicin 5Cisplatin 5Biopsy 5olaparib 4lenvatinib 4atezolizumab 4Radiotherapy 4Progestins 4Observation 4Nivolumab 4Megestrol Acetate 4Immunoglobulin G 4Gemcitabine 4trastuzumab deruxtecan 3palbociclib 3X-Rays 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Endometrial Neoplasms × CTLA-4 Antigen × Clear all
NCT05112601 2026-04-21

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
81 enrolled
Gynecologic

Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡